20th Feb 2007 15:34
This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan or any jurisdiction in which the same would be unlawful. This announcement is not an offer of securities in the United States, Canada, Australia, Japan or any jurisdiction in which the same would be unlawful.
20 February 2007
Shire plc ("Shire" or the "Company")
RESULT OF EQUITY PLACING
Shire is pleased to announce the successful completion of the placing announced earlier today (the "Placing").
A total of 42,883,721 new ordinary shares of 5 pence each in Shire (the "Placing Shares") have been placed by Morgan Stanley & Co. International Limited, Goldman Sachs International and Deutsche Bank, AG London Branch at a price of 1075 pence per Placing Share, raising gross proceeds of approximately $900 million (‚£461 million). The Placing Shares being issued represent approximately 8.4 per cent. of Shire's issued ordinary share capital prior to the Placing.
The Placing Shares will, when issued, be credited as fully paid and will rank equally in all respects with the existing issued ordinary shares of 5 pence each in the capital of the Company including the right to receive all future dividends and other distributions declared, made or paid in respect of such ordinary shares after the date of issue of the Placing Shares.
Application will be made for, and the Placing is conditional on, inter alia, admission of the Placing Shares to listing on the Official List maintained by the UK Listing Authority and admission to trading by the London Stock Exchange plc on its main market for listed securities (together, "Admission"). It is expected that Admission will become effective and dealings will commence in the Placing Shares at 8.00a.m. on 23 February 2007.
ENQUIRIES:
Goldman Sachs: Joshua Critchley - +44 20 7774 3109
Morgan Stanley: Peter Moorhouse & Jon Bathard-Smith - +44 20 7425 8000
Deutsche Bank: Charlie Foreman & Phil Cowdy - +44 20 7545 8000
This announcement has been issued by and is the sole responsibility of Shire.
Goldman Sachs International, Morgan Stanley & Co. International Limited and Deutsche Bank AG, London Branch are acting exclusively for Shire and no one else in relation to the matters described in this announcement and will not be responsible to anyone other than Shire for providing the protections afforded to customers of Goldman Sachs International, Morgan Stanley & Co. International Limited and Deutsche Bank AG, London Branch or for providing advice in relation to the matters referred to in this announcement.
This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice in any jurisdiction. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser.
The information contained in this announcement is not for release, publication or distribution, directly or indirectly in or into the United States, Canada, Australia or Japan or to US persons. This announcement is not an offer to buy or acquire any securities in the capital of the Company in the United States, Canada, Australia or Japan or any jurisdiction in which such offer or solicitation is unlawful and should not be relied upon in connection with any decision to acquire the Placing Shares or any other securities in the capital of the Company. The Placing Shares have not and will not be registered under the US Securities Act of 1933, as amended, or under the laws of any state of the United States and may not be offered or sold directly or indirectly, in the United States absent registration or an exemption from registration. In addition, the Placing Shares may not be offered or sold to, or for the account or benefit of, US persons (i) as part of their distribution or (ii) otherwise until 40 days after the closing date of the offering, except in either case in accordance with Regulation S under the US Securities Act of 1933. Terms used herein have the meanings given to them by Regulation S under the US Securities Act of 1933. There will be no public offering of securities in the United States, the United Kingdom or anywhere else.
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to: risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD), SPD465 (extended release of mixed amphetamine salts) (ADHD), and VYVANSE (NRP104) (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire's ability to complete, and achieve anticipated benefits from the acquisition of New River Pharmaceuticals; Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission.
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592 Registered Office as above
SHIRE PLCRelated Shares:
Shire